CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective Cytochrome P450 (CYP) enzymatic activity, which is influenced by CYP genetic polymorphism, is known to affect the inter-individual variation in the efficacy and tolerability of antidepressants in major depressive disorder (MDD). Escitalopram is metabolized by CYP2D6, and recent studies have reported a correlation between clinical outcomes and CYP2D6 genetic polymorphism. The purpose of this study was to determine the relationship between the CYP2D6 P34S polymorphism (C188T, rs1065852) and the efficacy of escitalopram treatment in Korean patients with MDD. Methods A total of 94 patients diagnosed with MDD were recruited for the study and their symptoms were evaluated using the 21-item Hamilton Depression Rating scale (HAMD-21). The association between the CYP2D6 P34S polymorphism and the clinical outcomes (remission and response) was investigated after 1, 2, 4, 8, and 12 weeks of escitalopram treatment using multiple logistic regression analysis and χ2 test. Results The proportion of P allele carriers (PP, PS) in remission status was greater than that of S allele homozygotes (SS) after 8 and 12 weeks of escitalopram treatment. Similarly, P allele carriers exhibited a greater treatment response after 8 and 12 weeks of escitalopram treatment than S allele homozygotes. Conclusion Our results suggest that the P allele of the CYP2D6 P34S polymorphism is a favorable factor in escitalopram treatment for MDD, and that the CYP2D6 P34S polymorphism may be a good genetic marker for predicting escitalopram treatment outcomes.
Abstract
Objective Cytochrome P450 (CYP) enzymatic activity, which is influenced by CYP genetic polymorphism, is known to affect the inter-individual variation in the efficacy and tolerability of antidepressants in major depressive disorder (MDD). Escitalopram is metabolized by CYP2D6, and recent studies have reported a correlation between clinical outcomes and CYP2D6 genetic polymorphism. The purpose of this study was to determine the relationship between the CYP2D6 P34S polymorphism (C188T, rs1065852) and the efficacy of escitalopram treatment in Korean patients with MDD. Methods A total of 94 patients diagnosed with MDD were recruited for the study and their symptoms were evaluated using the 21-item Hamilton Depression Rating scale (HAMD-21). The association between the CYP2D6 P34S polymorphism and the clinical outcomes (remission and response) was investigated after 1, 2, 4, 8, and 12 weeks of escitalopram treatment using multiple logistic regression analysis and χ2 test. Results The proportion of P allele carriers (PP, PS) in remission status was greater than that of S allele homozygotes (SS) after 8 and 12 weeks of escitalopram treatment. Similarly, P allele carriers exhibited a greater treatment response after 8 and 12 weeks of escitalopram treatment than S allele homozygotes. Conclusion Our results suggest that the P allele of the CYP2D6 P34S polymorphism is a favorable factor in escitalopram treatment for MDD, and that the CYP2D6 P34S polymorphism may be a good genetic marker for predicting escitalopram treatment outcomes.
참고문헌 (48)
- Duffy A, "The implications of genetics studies of major mood disorders for clinical practice", J Clin Psychiatry, 61, pp.630~637 (2000)
- Kelly K, "Toward achieving optimal response: understanding and managing antidepressant side effects", Dialogues Clin Neurosci, 10, pp.409~418 (2008)
- Khan A, "Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports", Neuropsychopharmacology, 28, pp.552~557 (2003)
- Hamdani N, "Role of genetics in psychiatric treatment", Presse Med, 37, pp.902~911 (2008)
- Nebert DW, "Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist", Am J Hum Genet, 60, pp.265~271 (1997)
- Baldwin DS, "Escitalopram therapy for major depression and anxiety disorders", Ann Pharmacother, 41, pp.1583~1592 (2007)
- Rao N, "The clinical pharmacokinetics of escitalopram", Clin Pharmacokinet, 46, pp.281~290 (2007)
- Kobayashi K, "Identification of cytochrome P450 isoforms involved in citalopram Ndemethylation by human liver microsomes", J Pharmacol Exp Ther, 280, pp.927~933 (1997)
- von Moltke LL, "Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram", Drug Metab Dispos, 29, pp.1102~1109 (2001)
- Reis M, "Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992-1997", Ther Drug Monit, 25, pp.183~191 (2003)
- Bertilsson L., "Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects", Clin Pharmacol Ther, 82, pp.606~609 (2007)
- Sachse C, "Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences", Am J Hum Genet, 60, pp.284~295 (1997)
- Garcia-Barcelo M, "Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population", Clin Chem, 46, pp.18~23 (2000)
- Lee MS, "Role of genetic polymorphisms related to neurotransmitters and cytochrome P-450 enzymes in response to antidepressants", Drugs Today (Barc), 43, pp.569~581 (2007)
- Lobello KW, "Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder", J Clin Psychiatry, 71, pp.1482~1487 (2010)
- Mulder H, "The association between cytochrome P450 2D6 genotype and prescription patterns of antipsychotic and antidepressant drugs in hospitalized psychiatric patients: a retrospective follow-up study", J Clin Psychopharmacol, 25, pp.188~191 (2005)
- Rau T, "CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study", Clin Pharmacol Ther, 75, pp.386~393 (2004)
- D’Empaire I, "Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant", J Psychiatr Pract, 17, pp.330~339 (2011)
- Tsai MH, "Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response", Pharmacogenomics, 11, pp.537~546 (2010)
- "The Human Cytochrome P450 (CYP) Allele" (2013)[URL]
- Ingelman-Sundberg M, "Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy", J Intern Med, 250, pp.186~200 (2001)
- Nishida Y, "CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10", Pharmacogenetics, 10, pp.567~570 (2000)
- Ji L, "Singlestep assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel*14B allele in mainland Chinese", Clin Chem, 48, pp.983~988 (2002)
- Lee SY, "Sequence-based CYP2D6 genotyping in the Korean population", Ther Drug Monit, 28, pp.382~387 (2006)
- Sakuyama K, "Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57)", Drug Metab Dispos, 36, pp.2460~2467 (2008)
- Johansson I, "Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation", Mol Pharmacol, 46, pp.452~459 (1994)
- Zhou SF, "Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I", Clin Pharmacokinet, 48, pp.689~723 (2009)
- Heim MH, "Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6", Genomics, 14, pp.49~58 (1992)
- Si-On Jeon, "CYP2D6 P34S Polymorphism and Mirtazapine Responses in Koreans with Major Depression", Molecular & Cellular Toxicology, 5(4), pp.346~353 (2009), 대한독성 유전단백체 학회
- Frank E, "Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence", Arch Gen Psychiatry, 48, pp.851~855 (1991)
- Kim JH, "Reliability and validity of the Korean version of UKU-SERS-Pat in patients with bipolar disorder", Nord J Psychiatry, 62, pp.496~502 (2008)
- Bertilsson L, "Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs", Br J Clin Pharmacol, 53, pp.111~122 (2002)
- Kirchheiner J, "CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages", Acta Psychiatr Scand, 104, pp.173~192 (2001)
- Preskorn S, "Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers", J Clin Psychopharmacol, 29, pp.39~43 (2009)
- Ueda M, "The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients", Prog Neuropsychopharmacol Biol Psychiatry, 30, pp.486~491 (2006)
- LLerena A, "Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions", Eur J Clin Pharmacol, 59, pp.869~873 (2004)
- Ohara K, "CYP2D6* 10 alleles do not determine plasma fluvoxamine concentration", dose ratio in Japanese subjects, 2003, pp.58, 659~661
- Zhou SF, "Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II", Clin Pharmacokinet, 48, pp.761~804 (2009)
- Bijl MJ, "Association between the CYP2D6*4 polymorphism and depression or anxiety in the elderly", Pharmacogenomics, 10, pp.541~547 (2009)
- Gerstenberg G, "Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients", Psychopharmacology (Berl), 167, pp.443~448 (2003)
- Murphy GM Jr, "Pharmacogenetics of antidepressant medication intolerance", Am J Psychiatry, 160, pp.1830~1835 (2003)
- Serretti A, "Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients", Int Clin Psychopharmacol, 24, pp.250~256 (2009)
- Chou WH, "Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness", J Clin Psychopharmacol, 20, pp.246~251 (2000)
- Shams ME, "CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine", J Clin Pharm Ther, 31, pp.493~502 (2006)
- Zourkova A, "Links among paroxetine- induced sexual dysfunctions, gender, and CYP2D6 activity", J Sex Marital Ther, 33, pp.343~355 (2007)
- Kawanishi C, "Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse", A pilot study. Eur J Clin Pharmacol, 59, pp.803~807 (2004)
- Breil F, "Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype", Int J Neuropsychopharmacol, 11, pp.727~728 (2008)
- Grasmader K, "Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting", Eur J Clin Pharmacol, 60, pp.329~336 (2004)